Tech Company Financing Transactions
DermBiont Funding Round
On 10/24/2023, DermBiont announced $35.2 million in Series B funding from Double Point Ventures, private investors and Viking Global Investors.
Transaction Overview
Company Name
Announced On
10/24/2023
Transaction Type
Venture Equity
Amount
$35,200,000
Round
Series B
Investors
Double Point Ventures (Lead Investor)
Proceeds Purpose
The company intends to use the funds to advance two drugs in development, SM-020, a topical novel AKT kinase inhibitor for the treatment of seborrheic keratoses (SKs), and SM-030, a topical novel PKC-beta inhibitor for the treatment of melasma and other hyperpigmentation disorders of the skin.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
75 Kneeland St. 14th Floor
Boston, MA 02118
USA
Boston, MA 02118
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
DermBiont develops skin microbiome therapeutics platform to treat and prevent skin diseases. DermBiont is at the intersection of two highly active sectors: dermatology and the microbiome. They harness naturally occurring microbes on the human skin that have evolved over hundreds of thousands of years to compete with pathogenic microbes.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 10/24/2023: Qosmosys venture capital transaction
Next: 10/24/2023: Aleph venture capital transaction
Share this article
About Database of VC Transactions
We do our best to record tech company VC transactions. VC transactions reported here are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs